Extended Analyses of the German IVF Registry (DIR): Andrological Aspects, Medical-Economical Assumptions Related to the Shift from IVF to ICSI and Stimulation with Gonadotropins

Bals-Pratsch M, Bühler K, Krüssel J, Wendelken M
Dahncke W, Kupka MS

J. Reproduktionsmed. Endokrinol 2010; 7 (1), 40-44
Practical Aspects

Medical indications rather than economic reasons seem to be responsible for the increase in ICSI treatment. Seven percent of ICSI cycles are performed with testicular or epididymal sperm. In these cases miscarriage and birth rates are not reduced. GnRH antagonist protocols play an increasing part in routine ART cycles.

Introduction

For the second time, a lunch symposium was held during the annual meeting of the German IVF groups in Freiburg in November 2009 with the presentation of the special statistical evaluations in addition to the annual report of the German IVF Registry (D·I·R). The data were presented by members of the directorial board and the board of trustees. In the 2008 lunch symposium, a detailed analysis of ART cycles for regional differences in success rates, clinical aspects of GnRH agonist and antagonist protocols and IVF quality had been assessed anonymously for individual IVF centers [1]. The topics of the current symposium were male infertility, ICSI treatment and stimulation with urinary or recombinant gonadotropins in clinical routine.

Indications and Results of ART Cycles for Male Infertility

ICSI cycles have been registered in the D·I·R since 1994 [2]. By 1999, all D·I·R centers in Germany practiced both IVF and ICSI techniques and between 2001 and 2004 one or two centers only documented ICSI cycles. TheESHRE European IVF Monitoring (EIM) recorded the trend in IVF practice with ICSI cycles exceeding the frequency of IVF cycles in 2002 in Europe [3]. In the current analysis of andrological aspects in

Table 1: Retrieval of sperm for ART cycles in the German IVF Registry (D·I·R) 1998–2008.

<table>
<thead>
<tr>
<th>Frequency (n)</th>
<th>Cumulative frequency (n)</th>
<th>Percentage (%)</th>
<th>Cumulative percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not specified</td>
<td>7202</td>
<td>7202</td>
<td>2.38</td>
</tr>
<tr>
<td>Antegrade ejaculation</td>
<td>267,572</td>
<td>274,774</td>
<td>88.48</td>
</tr>
<tr>
<td>Retrograde ejaculation</td>
<td>229</td>
<td>275,003</td>
<td>0.08</td>
</tr>
<tr>
<td>Cryopreserved sperm</td>
<td>5,337</td>
<td>280,340</td>
<td>1.76</td>
</tr>
<tr>
<td>Microsurgical epididymal sperm aspiration (MESA)</td>
<td>185</td>
<td>280,525</td>
<td>0.06</td>
</tr>
<tr>
<td>Cryopreserved sperm after MESA</td>
<td>624</td>
<td>281,149</td>
<td>0.21</td>
</tr>
<tr>
<td>Percutaneous epididymal sperm aspiration (PESA)</td>
<td>32</td>
<td>281,181</td>
<td>0.01</td>
</tr>
<tr>
<td>Cryopreserved sperm after PESA</td>
<td>15</td>
<td>281,196</td>
<td>0.00</td>
</tr>
<tr>
<td>Testicular sperm extraction (TESE)</td>
<td>4,260</td>
<td>285,456</td>
<td>1.41</td>
</tr>
<tr>
<td>TESE of cryopreserved testicular tissue</td>
<td>16,143</td>
<td>301,599</td>
<td>5.34</td>
</tr>
<tr>
<td>Electro-ejaculation</td>
<td>41</td>
<td>301,640</td>
<td>0.01</td>
</tr>
<tr>
<td>Artificial spermatocele</td>
<td>11</td>
<td>301,651</td>
<td>0.00</td>
</tr>
<tr>
<td>Donor sperm</td>
<td>762</td>
<td>302,413</td>
<td>0.25</td>
</tr>
</tbody>
</table>
ART, 302,413 cycles registered between 1998 and 2008 by the D-I-R were analysed.

Sperm Retrieval for ART Cycles
The indication for an ICSI procedure is related to the retrieval of sperm in the mandatory field in the D-I-R database (Tab. 1). Indications for IVF or ICSI treatment can be derived from the origin of sperm for ART (Fig. 1): male factor (poor sperm quality, antegrade ejaculation), obstructive or non-obstructive azoospermia (MESA, PESA, TESE or artificial spermatocele), retrograde ejaculation (sperm retrieved from urine, electro-stimulation or antegrade ejaculation after medication), male fertility preservation (cryopreserved sperm) or male ART treatment failure (cryopreserved donor sperm). Seven percent of all ART cycles in the German registry were performed with epididymal or testicular sperm due to azoospermia. But no differentiation can be carried out between non-obstructive and obstructive azoospermia and fertilization and pregnancy results cannot be distinguished between cycles with intracytoplasmatic injection of motile and immotile testicular sperm (no mandatory fields). The number of ART cycles with testicular or cryopreserved ejaculated sperm is increasing (Fig. 2). Fluctuations in the numbers of treatment cycles in 2000 and 2004 are due to changes in the reimbursement of ICSI cycles by the public health insurance. 20,403 TESE cycles and 5,337 cycles with cryopreserved...
sperm were performed between 1998 and 2008.

### Success Rates and Sperm Retrieval

Lower fertilization and pregnancy rates are expected when ART cycles are performed with poor sperm quality or even testicular sperm. The analysis of 293,312 cycles with ejaculated, cryopreserved or testicular sperm confirmed this assumption. Fertilization and pregnancy rates were lowest with testicular sperm ($p < 0.05$). But when a pregnancy can be achieved the birth rate seems to be highest and the risk for multiple pregnancies lower than with ejaculated sperm (Fig. 3). Although pregnancy rates are higher for cryopreserved ejaculated sperm in comparison to testicular sperm, the annual analysis of 11 years reveals an improvement in pregnancy rates with almost similar success rates for cryopreserved and testicular sperm (Fig. 4).

### Lifestyle and ART Cycles

Alcohol, smoking, over- but also underweight are known risk factors for infertility problems in women and men. Especially the prevalence of obesity and infertility is increasing in the developed world.

The body mass index (BMI) can be calculated for women and men in the database of the D·I·R because body weight and height are mandatory fields. However, the analysis of these data revealed that the data entered are incomplete or incorrect. According to the analysis of the BMI data only 2.5 % of the infertile men, 6.3 % of the infertile women and 0.7 % of both partners were overweight with a BMI > 30 (expected 17 % for married men and 14 % for married women [4]). Nevertheless, the miscarriage rate for women with obesity was significantly higher in comparison to women with a BMI < 30 and is possibly due to metabolic disorders [2]. Smoking habits are also recorded in the D·I·R database (mandatory field for pre-existing diseases). The data analysis for nicotine abuse gave invaluable results probably also due to incomplete data collection and data entering [2]. All D·I·R centers should be encouraged to improve their data collection at least for main lifestyle parameters like body weight, height and smoking habits. Thus these D·I·R data can become valuable for the future.

### Considerations on the Increase of IVF to ICSI

Reimbursement policies can have significant impact on the accessibility and use of ART treatments, and lack of medical reimbursement will act as a barrier to the use of ART. The analysis of the D·I·R data demonstrate that no reimbursement for ICSI cycles by the public health insurance in the year 2000 re-
Stimulation with Gonadotropins

Since the commercial launch of GnRH antagonists in 1999 (cetrorelix) and 2000 (ganirolex) stimulation protocols with GnRH antagonists have become routine in ART cycles. Meanwhile > 90 % of IVF and ICSI protocols in Germany are performed with GnRH agonists (54.8 %) and GnRH antagonists (31.5 %) (Tab. 2). This is in accordance with the current trend in ART practice worldwide [6]. Especially in PCOS patients with a higher risk for ovarian hyperstimulation syndrome (OHSS), but also in common ART patients, GnRH antagonists are favoured by more and more clinicians on an individualized patient-centered approach including flexible administration of GnRH antagonists or even the use of a GnRH agonist to trigger final oocyte maturation and ovulation [7, 8]. Pregnancy rates improved for antagonist protocols particularly because less poor responder but more normal or high responder patients with normal ovarian function are treated with this protocol.

Approximately 90 % of the IVF and ICSI cycles in Germany are performed with recombinant FSH (rFSH), highly purified menotropin (HP-hMG), or a combination of both (Tab. 2). In the majority of the GnRH agonist long-protocol cycles rFSH preparations were used. Less than 50 % of the GnRH antagonist cycles were performed with rFSH. In these cycles nearly 40 % were carried out with rFSH in combination with HP-hMG, while in cycles with the long protocol < 20 % were stimulated with the combination of rFSH and HP-hMG. Possibly clinicians try to react to the drop in estradiol concentration due to the suppression of endogenous LH by GnRH antagonists with the administration of exogenous LH by HP-hMG preparations. However, pregnancy rates are only comparable in the GnRH agonist long (32.3 %) and the antagonist protocol (29.6 %) when the stimulation is performed with rFSH.

Pregnancy rates are significantly lower in cycles stimulated with hMG in comparison to rFSH (Fig. 11) independent of further variables such as the stimulation protocol, maternal age or dosage of gonadotropins (no mandatory field for the D-I-R). No general recommendation can

---

Table 2: Percentage of cycles with embryo transfer (ET) and pregnancy rate (PR) in relation to different stimulation protocols and gonadotropin preparations, German IVF Registry (D-I-R) 2008.

<table>
<thead>
<tr>
<th>Gonadotropin preparation/ Stimulation protocol</th>
<th>uFSH</th>
<th>rFSH</th>
<th>hMG</th>
<th>rFSH plus rLH</th>
<th>rFSH plus HP-hMG</th>
<th>Others</th>
<th>n. s.</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>GnRH agonist, short (n)</td>
<td>168</td>
<td>1,573</td>
<td>1,384</td>
<td>85</td>
<td>508</td>
<td>28</td>
<td>3</td>
<td>3,749</td>
</tr>
<tr>
<td>ET (%)</td>
<td>94.6</td>
<td>93.0</td>
<td>92.2</td>
<td>81.2</td>
<td>90.2</td>
<td>96.4</td>
<td>66.7</td>
<td>92.1</td>
</tr>
<tr>
<td>PR (%)</td>
<td>26.4</td>
<td>23.9</td>
<td>23.7</td>
<td>275</td>
<td>15.8</td>
<td>15.4</td>
<td>50.0</td>
<td>22.9</td>
</tr>
<tr>
<td>GnRH agonist, long (n)</td>
<td>258</td>
<td>11,973</td>
<td>4,215</td>
<td>1,714</td>
<td>3,327</td>
<td>203</td>
<td>5</td>
<td>21,695</td>
</tr>
<tr>
<td>ET (%)</td>
<td>90.3</td>
<td>92.4</td>
<td>93.6</td>
<td>90.4</td>
<td>93.8</td>
<td>89.7</td>
<td>80.0</td>
<td>92.7</td>
</tr>
<tr>
<td>PR (%)</td>
<td>30.5</td>
<td>32.7</td>
<td>30.3</td>
<td>33.1</td>
<td>32.2</td>
<td>25.8</td>
<td>25.0</td>
<td>31.7</td>
</tr>
<tr>
<td>No GnRH analogues (n)</td>
<td>4</td>
<td>770</td>
<td>333</td>
<td>69</td>
<td>152</td>
<td>183</td>
<td>175</td>
<td>1,686</td>
</tr>
<tr>
<td>ET (%)</td>
<td>75.0</td>
<td>93.5</td>
<td>89.8</td>
<td>91.3</td>
<td>89.5</td>
<td>83.1</td>
<td>76.6</td>
<td>89.4</td>
</tr>
<tr>
<td>PR (%)</td>
<td>33.3</td>
<td>32.9</td>
<td>28.4</td>
<td>22.2</td>
<td>30.2</td>
<td>19.1</td>
<td>9.7</td>
<td>27.9</td>
</tr>
<tr>
<td>Antagonist (n)</td>
<td>93</td>
<td>6,760</td>
<td>2,063</td>
<td>780</td>
<td>1,450</td>
<td>1317</td>
<td>12</td>
<td>12,475</td>
</tr>
<tr>
<td>ET (%)</td>
<td>93.6</td>
<td>92.7</td>
<td>88.6</td>
<td>86.3</td>
<td>90.3</td>
<td>88.4</td>
<td>100</td>
<td>90.9</td>
</tr>
<tr>
<td>PR (%)</td>
<td>9.2</td>
<td>29.6</td>
<td>24.2</td>
<td>25.6</td>
<td>23.5</td>
<td>23.5</td>
<td>8.3</td>
<td>27.0</td>
</tr>
<tr>
<td>Total (n)</td>
<td>523</td>
<td>21,076</td>
<td>7,995</td>
<td>2,648</td>
<td>5,437</td>
<td>1,731</td>
<td>195</td>
<td>39,605</td>
</tr>
<tr>
<td>Total (%)</td>
<td>1.3</td>
<td>53.7</td>
<td>20.2</td>
<td>6.7</td>
<td>13.7</td>
<td>4.4</td>
<td>0.5</td>
<td>53.7</td>
</tr>
</tbody>
</table>

Abbreviations: urinary FSH (uFSH), recombinant FSH (rFSH), highly purified menotropin (HP-hMG), rFSH plus HP-hMG, recombinant LH (rLH), not specified (n.s.), short GnRH protocol (microdose flare-up protocol), cycles to embryo transfer (ET), pregnancy rate per embryo transfer (PR).
be derived from this fact, because the stimulation of a patient should be individualized which includes the prediction of ovarian response and reduction of the risk for OHSS. Moreover, in a randomized controlled study with oocyte donors no difference was detected between the stimulation with rFSH, hMG or a combination of rFSH and hMG regarding ovarian response and IVF outcome [9]. Interestingly, non-medical factors can influence the choice of gonadotropins for stimulation. Figure 12 demonstrates very clearly the impact of costs for the increase in cycles stimulated with hMG and the decrease in cycles stimulated with rFSH in 2000 for ICSI and 2004 for IVF and ICSI. In those years hMG, not highly purified, was still commercially and considerably cheaper than rFSH. Between 1997 and 2000 ICSI cycles were not reimbursed by the public health insurance and in 2004 the 50 % co-pay-
ment for treatment and medication was established by the public health insurance. Thus patients decided to prefer hMG preparations for ART stimulation. Meanwhile the prices for rFSH and HP-
hMG have become similar and non-puri-
fied hMG preparations have disappeared from the national and neighbourhood pharmaceutical market.

The analysis of the cycle cancellation rate and pregnancy rate relating to maternal age and rFSH or hMG preparations gives a clear advantage for rFSH in women beyond 34 but not for younger women. Since 2003 the percentage of stimulated cycles leading to oocyte retrieval and the pregnancy rate per transfer have been significantly higher when the stimulation was performed with rFSH (Fig. 13, 14).

The Lunch Symposium was sponsored by Merck-Serono.

References:
5. Balo-Pratsch M, Gagsteiger F, van der Ven H. Nachweis situation in Gynäkologischer Endokrinologie und Reproduktions-
7. Lainas TG, Shontumir IA, Zaroulii IZ, Petrou GI, Lainas GT, Alexopoulou E, Kolibianakis EM. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with poly-
cystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod 2010; (in press).
9. Meis M, Belter J, Garrido N, Meseguer M, Policar A, Remahi J. A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian re-
sponse, in vitro fertilization outcome, and analysis of cost mini-
Mitteilungen aus der Redaktion

Besuchen Sie unsere Rubrik

☑️ Medizintechnik-Produkte

Neues CRT-D Implantat
Intica 7 HFT OP von Biotronik

Aspirator 3
Labotect GmbH

Artis pheno
Siemens Healthcare Diagnostics GmbH

Philips Azurion:
Innovative Bildgebungslösung

InControl 1050
Labotect GmbH

e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.
Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.
Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☑️ Bestellung e-Journal-Abo

Haftungsausschluss


Bitte beachten Sie auch diese Seiten:

Impressum
Disclaimers & Copyright
Datenschutzerklärung